Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes

Show full item record



Permalink

http://hdl.handle.net/10138/314705

Citation

Alkodsi , A , Cervera , A , Zhang , K , Louhimo , R , Meriranta , L , Pasanen , A , Leivonen , S-K , Holte , H , Leppä , S , Lehtonen , R & Hautaniemi , S 2019 , ' Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes ' , Leukemia , vol. 33 , no. 11 , pp. 2662-2672 . https://doi.org/10.1038/s41375-019-0509-6

Title: Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes
Author: Alkodsi, Amjad; Cervera, Alejandra; Zhang, Kaiyang; Louhimo, Riku; Meriranta, Leo; Pasanen, Annika; Leivonen, Suvi-Katri; Holte, Harald; Leppä, Sirpa; Lehtonen, Rainer; Hautaniemi, Sampsa
Contributor: University of Helsinki, Sampsa Hautaniemi / Principal Investigator
University of Helsinki, Sampsa Hautaniemi / Principal Investigator
University of Helsinki, Research Program in Systems Oncology
University of Helsinki, Research Program in Systems Oncology
University of Helsinki, ATG - Applied Tumor Genomics
University of Helsinki, HUS Comprehensive Cancer Center
University of Helsinki, Research Programs Unit
University of Helsinki, Department of Oncology
University of Helsinki, Research Program in Systems Oncology
University of Helsinki, Sampsa Hautaniemi / Principal Investigator
Date: 2019-11
Language: eng
Number of pages: 11
Belongs to series: Leukemia
ISSN: 0887-6924
URI: http://hdl.handle.net/10138/314705
Abstract: Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous disease whose personalized clinical management requires robust molecular stratification. Here, we show that somatic hypermutation (SHM) patterns constitute a marker for DLBCL molecular classification. The activity of SHM mutational processes delineated the cell of origin (COO) in DLBCL. Expression of the herein identified 36 SHM target genes stratified DLBCL into four novel SHM subtypes. In a meta-analysis of patients with DLBCL treated with immunochemotherapy, the SHM subtypes were significantly associated with overall survival (1642 patients) and progression-free survival (795 patients). Multivariate analysis of survival indicated that the prognostic impact of the SHM subtypes is independent from the COO classification and the International Prognostic Index. Furthermore, the SHM subtypes had a distinct clinical outcome within each of the COO subtypes, and strikingly, even within unclassified DLBCL. The genetic landscape of the four SHM subtypes indicated unique associations with driver alterations and oncogenic signaling in DLBCL, which suggests a possibility for therapeutic exploitation. These findings provide a biologically driven classification system in DLBCL with potential clinical applications.
Subject: CHEMOTHERAPY PLUS RITUXIMAB
SOMATIC MUTATIONS
SIGNATURES
SURVIVAL
CLASSIFICATION
DISCOVERY
TARGETS
GENOME
CHOP
AID
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Alkodsi_et_al_manuscript.pdf 779.6Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record